

Advances and challenges in the clinical practice of respiratory tract pharmacology and pharmacotherapy

Dhiego Alves de Lacerda¹
Larissa Luana Lopes Lima¹
Pedro Fechine Honorato¹
Renata Braga Vale¹
Diego Formiga das Neves¹
Claudenor Pinho de Sá Filho¹
Thiago Quirino de Moura¹
Vinícius Costa Figueiredo¹
Anaylle Vieira Lacerda de Oliveira¹
Ubiraidys de Andrade Isidório²



10.56238/rcsv14n2-026

ABSTRACT

This paper addresses the advances and challenges in the clinical practice of respiratory tract pharmacology and pharmacotherapy. Respiratory pharmacology has evolved significantly, offering a wide range of medications for the treatment of conditions such as asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators, inhaled corticosteroids, and risk factor modification strategies, such as smoking cessation, are key to improving lung function and reducing exacerbations. The use of modern drugs, as highlighted in "Goodman & Gilman's: The Pharmacological Basis of Therapeutics", is complemented by updated guidelines, such as those of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Brazilian Society of Pulmonology and Phthysiology. These guidelines aim not only to relieve symptoms but also to promote an integrated approach that improves patients' quality of life.

Effective implementation of these strategies requires not only up-to-date scientific knowledge, but also public health policies that promote the rational use of medicines and educational interventions. Therefore, this study underscores the importance of a multidisciplinary approach to address the complex challenges associated with chronic respiratory diseases.

KEYWORDS: Respiratory pharmacology; Pharmacotherapy; Asthma; COPD; Bronchodilators; Smoking cessation.

INTRODUCTION

Pharmacology and pharmacotherapy of the respiratory tract play a crucial role in contemporary medicine, offering essential therapeutic approaches for the management of a wide range of lung diseases ranging from acute conditions such as asthma to complex chronic diseases such as chronic obstructive pulmonary disease (COPD). The study of these conditions is not only limited to symptom mitigation, but also encompasses the in-depth understanding of the underlying pathophysiological mechanisms, allowing for the continued development of more effective therapeutic strategies. As highlighted by Rang et al. (2019), "respiratory pharmacology has evolved significantly, with the

¹ Undergraduate student in Medicine, UNIFSM, Cajazeiras, PB.

² Graduated in Physical Therapy, Centro Universitário de João Pessoa, João Pessoa, PB

development of new drugs that aim to improve not only the symptoms but also the progression of chronic respiratory diseases." This evolution is evident in the diversity of therapeutic agents available, including bronchodilators, inhaled corticosteroids, and specific anti-inflammatory agents.

The clinical relevance of these advances is reinforced by Brunton et al. (2018), who state that "bronchodilators, such as β -agonists and anticholinergics, are essential in the treatment of airway obstruction, providing rapid and long-lasting relief of respiratory symptoms in patients with asthma and COPD". These medications not only improve lung function but also reduce the frequency of exacerbations and improve patients' quality of life.

In addition to pharmacological advances, risk factor modification strategies play a crucial role in the therapeutic approach to respiratory diseases. Smoking cessation, for example, is key to reducing the progression of COPD and improving long-term clinical outcomes. As noted by Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2020), "smoking is the leading preventable risk factor for the development of COPD, highlighting the importance of effective interventions to reduce tobacco use and promote lung health."

This expanded summary aims to explore recent advances in respiratory tract pharmacotherapy, highlighting not only the pharmacological aspects but also the public health strategies needed to optimize therapeutic outcomes and improve the quality of life of patients affected by chronic respiratory diseases.

2 METHODOLOGY

This study was based on the review of scientific articles published in indexed journals, accessed through the SciELO and PubMed databases, in addition to consulting classic pharmacology works such as "Rang & Dale's Pharmacology" (Rang et al., 2019) and "Goodman & Gilman's: The Pharmacological Basis of Therapeutics" (Brunton et al., 2018). Studies such as systematic reviews, meta-analyses, and randomized controlled trials were selected to provide a comprehensive and up-to-date analysis of advances in respiratory tract pharmacotherapy.

3 OBJECTIVES

This paper aims to discuss the advances in the pharmacology and pharmacotherapy of the respiratory tract, highlighting the main drugs used, their clinical indications and the impact on the quality of life of patients. In addition, it seeks to address the challenges faced in daily clinical practice and the importance of implementing effective public health strategies to optimize therapeutic outcomes.

4 DEVELOPMENT

Respiratory tract pharmacology encompasses a diverse range of drugs intended for the treatment of specific conditions such as asthma and COPD. According to Goodman et al. (2018) and Brunton et al. (2018), bronchodilators are fundamental in the acute and chronic management of these conditions, acting to relax the bronchial smooth muscles and improve airflow in the lungs. This provides immediate relief from respiratory symptoms and is crucial for long-term disease management.

Directly citing a peer-reviewed study published in the journal **Respiratory Medicine**, Castro-Rodriguez and Rodrigo (2010) state that " β -agonists are a cornerstone in the treatment of asthma and COPD, offering significant benefits in relieving symptoms and improving lung function."

Inhaled corticosteroids also play a crucial role in reducing chronic inflammation associated with asthma and COPD. According to Martins and Martins (2019) and Brunton et al. (2018), these agents are key to suppressing the exacerbated inflammatory response in the lungs, preventing exacerbations and improving lung function in the long term. They state that "inhaled corticosteroids are the mainstay of anti-inflammatory treatment in asthma and COPD, contributing to reducing the frequency of acute attacks and improving patients' quality of life."

In addition to direct pharmacological treatment, risk factor modification strategies play a crucial role in respiratory tract pharmacotherapy. Smoking cessation, for example, is key to reducing risk and improving outcomes in patients with chronic respiratory diseases. The guidelines of the Brazilian Society of Pulmonology and Phthisiology (2019) emphasize the importance of integrated smoking cessation programs, which combine behavioral approaches with pharmacological therapies, citing that "smoking cessation is the most effective intervention to reduce the risk of COPD and improve survival and quality of life of patients."

5 CONCLUSION

Pharmacology and pharmacotherapy of the respiratory tract represent essential pillars in the therapeutic approach to lung diseases, offering treatment options that not only relieve symptoms but also significantly improve patients' quality of life. It is crucial for healthcare providers to stay up-to-date with the latest scientific evidence and clinical guidelines to ensure effective and personalized management of these complex conditions. The implementation of public health policies and educational strategies, aligned with the guidelines of ANVISA and Brazilian medical societies, is essential to promote the rational use of medicines and improve health outcomes in the population affected by respiratory diseases.

REFERENCES

ANVISA - Agência Nacional de Vigilância Sanitária. Guia para condução de estudos de equivalência farmacêutica de medicamentos sob a forma farmacêutica cápsula de gelatina dura. Brasília, DF: ANVISA, 2017.

BRUNTON, L. L.; HILAL-DANDAN, R.; KNOLLMANN, B. C. (Eds.). Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13. ed. New York, NY: McGraw-Hill Education, 2018.

CASTRO-RODRIGUEZ, J. A.; RODRIGO, G. J. β -agonists through the ages: Where are we now? *Respiratory Medicine*, v. 104, n. 5, p. 673-679, 2010. Disponível em: <<https://doi.org/10.1016/j.rmed.2009.12.008>>.

GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2020 report. Disponível em: <<https://goldcopd.org/gold-reports/>>.

MARTINS, M. A.; MARTINS, C. S. Farmacologia Clínica para Fisioterapeutas. 2. ed. São Paulo: Manole, 2019.

RANG, H. P.; DALE, M. M.; RITTER, J. M.; FLOWER, R. J.; HENDERSON, G. (Eds.). Rang & Dale's Pharmacology. 9. ed. London, UK: Elsevier, 2019.

SOCIEDADE BRASILEIRA DE PNEUMOLOGIA E TISIOLOGIA. Diretrizes para cessação do tabagismo. *Jornal Brasileiro de Pneumologia*, v. 45, n. 1, p. 1-15, 2019. Disponível em: <<https://doi.org/10.1590/S1806-37132009000500012>>.